Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Acquired by Fmr LLC

Fmr LLC grew its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 0.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,292,881 shares of the company’s stock after purchasing an additional 9,115 shares during the period. Fmr LLC owned approximately 0.15% of Krystal Biotech worth $781,433,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Dimensional Fund Advisors LP lifted its stake in shares of Krystal Biotech by 1.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company’s stock valued at $106,593,000 after purchasing an additional 7,537 shares in the last quarter. Hood River Capital Management LLC lifted its stake in shares of Krystal Biotech by 5.1% in the 2nd quarter. Hood River Capital Management LLC now owns 521,093 shares of the company’s stock valued at $95,694,000 after purchasing an additional 25,507 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Krystal Biotech by 9.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 240,216 shares of the company’s stock valued at $43,727,000 after purchasing an additional 19,777 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Krystal Biotech by 115.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company’s stock valued at $35,583,000 after purchasing an additional 103,928 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Krystal Biotech by 11.4% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 176,446 shares of the company’s stock valued at $32,402,000 after purchasing an additional 18,021 shares in the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on KRYS shares. Citigroup boosted their price target on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Evercore ISI boosted their price target on Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research report on Monday, August 12th. HC Wainwright reissued a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research report on Tuesday, November 5th. Stifel Nicolaus boosted their price target on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Krystal Biotech has a consensus rating of “Buy” and an average price target of $202.29.

Krystal Biotech Stock Up 0.2 %

KRYS stock opened at $196.91 on Thursday. Krystal Biotech, Inc. has a 52-week low of $99.00 and a 52-week high of $219.34. The stock’s 50 day moving average is $179.98 and its two-hundred day moving average is $183.19. The company has a market capitalization of $5.66 billion, a PE ratio of 111.25 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The business had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same period in the previous year, the business earned ($0.67) EPS. The business’s quarterly revenue was up 879.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now directly owns 1,500,882 shares in the company, valued at $296,814,424.32. This represents a 1.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 14.10% of the stock is owned by company insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).